Results 231 to 240 of about 8,117 (271)

Benralizumab for the treatment of asthma

Drugs of Today, 2017
Benralizumab is a humanized monoclonal antibody directed at the a subunit of the interleukin-5 receptor (IL-5R) that is under clinical development. The binding of benralizumab with the alpha chain of IL-5R results in inhibition of hetero-oligomerization of alpha and beta subunits and thus no signal transduction occurs.
Matera MG, Rogliani P, Calzetta L, Canonica GW, Cazzola M   +4 more
openaire   +7 more sources

Benralizumab: an updated treatment of eosinophilic asthma

Expert Review of Respiratory Medicine, 2020
Introduction: An estimated 5-10% of people with asthma have disease which remains uncontrolled despite maximal treatment with inhaled corticosteroids and long-acting beta-agonists. Benralizumab is currently licensed for use in patients with severe asthma who have an eosinophilic phenotype.
Andrew Menzies-Gow, Breda Cushen
openaire   +3 more sources

Treatment of Eosinophilic Annular Erythema With Benralizumab

JAMA Dermatology, 2023
This case report describes an 83-year-old woman with a generalized pruritic eruption comprising annular and polycyclic plaques on the face, neck, trunk, and extremities with changing appearance.
Fernando, Moro-Bolado, Laura, Martínez-Montalvo, Omar, Al-Wattar-Ceballos, Pedro Ángel, Galindo-Bonilla, Mónica, García-Arpa   +4 more
openaire   +2 more sources

Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme

European Respiratory Journal
Graphical abstract In this large, real-world programme, patients with severe eosinophilic asthma treated with benralizumab had substantial improvements in clinical outcomes, irrespective of previous biologic use and key clinical characteristics important
David J Jackson, G. Pelaia, Benjamin Emmanuel, Trung N. Tran, David Cohen, Vivian H Shih, A. Shavit, D. Arbetter, R. Katial, A. P. Rabe, E. Garcia Gil, M. Pardal, J. Nuevo, Michael Watt, S. Boarino, S. Kayaniyil, C. Chaves Loureiro, A. Padilla-Galo, P. Nair   +18 more
semanticscholar   +1 more source

Non-infective cystitis secondary to benralizumab immunotherapy

BMJ Case Reports, 2022
This case study discusses a patient who presented with severe lower urinary tract symptoms and pain after commencing immunotherapy for eosinophilic asthma. Initial aetiology was presumed to be infective but cultures were negative. Cross-sectional imaging showed extensive perivesical and periprostatic stranding and inflammation. He was initially treated
Toby Murray, Ben Haagsma, Andrew Chetwood   +2 more
openaire   +2 more sources

Benralizumab: for asthma, not yet for COPD

The Lancet Respiratory Medicine, 2014
Asthma and chronic obstructive pulmonary disease (COPD) are two distinct, chronic, inflammatory respiratory diseases.1,2 Asthma develops early in life, mainly in atopic individuals, and is characterised by airway hyper-responsiveness and recurrent wheezing due to a chronic inflammation of the airways caused by a CD4, T-helper type-2, eosinophilic ...
openaire   +3 more sources

Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase 2b multinational, randomised, double-blind, placebo-controlled ARROYO trial.

British Journal of Dermatology
BACKGROUND Chronic spontaneous urticaria (CSU) is a relatively common skin disease associated with hives and angio-oedema. Eosinophils play a role in CSU pathogenesis. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, has been shown
S. Altrichter, A. Giménez-Arnau, J. Bernstein, Martin Metz, L. Bahadori, Maria Bergquist, Laura Brooks, C. N. Ho, Priya Jain, Pradeep B. Lukka, E. Rodríguez-Suárez, C. Walton, Catherine J Datto   +12 more
semanticscholar   +1 more source

Benralizumab as a potential treatment of asthma

Expert Opinion on Biological Therapy, 2017
Current anti-inflammatory asthma therapies including inhaled corticosteroids and leukotriene modifiers, are not always able to appropriately control the disease and other approaches are needed. These therapies specific target IgE (omalizumab) or IL-5 (mepolizumab).
openaire   +2 more sources

Real-world clinical remission of severe asthma with benralizumab in Spanish adults with severe asthma

Journal of Asthma
Objective Patients with severe eosinophilic asthma experience high risk of exacerbations and reduced quality of life. Benralizumab, a monoclonal antibody binding to IL-5 receptor α subunit, is an approved drug for its treatment.
E. Martínez-Moragón, E. Chiner, Alexandra Suliana Mogrovejo, Marta Palop Cervera, Inmaculada Lluch Tortajada, Ignacio Boira Enrique, Andrés Fernando Sánchez Vera   +6 more
semanticscholar   +1 more source

Benralizumab: First Global Approval

Drugs, 2018
Kyowa Hakko Kirin, AstraZeneca and subsidiaries are developing benralizumab (Fasenra™)-a humanised anti-interleukin-5 receptor alpha chain (IL-5Rα) monoclonal antibody-as a treatment of severe eosinophilic asthma and chronic obstructive pulmonary disease (COPD).
openaire   +3 more sources